Journal
CLINICAL IMMUNOLOGY
Volume 123, Issue 1, Pages 114-120Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2006.11.007
Keywords
multiple myeloma; soluble MICA; NKG2D ligand; prognostic marker; overall survival; progression-free survival
Categories
Ask authors/readers for more resources
Major histocompatibility complex class I-related chain A (MICA) molecules are frequently expressed in lymphoproliferative malignancies including multiple myeloma (MM). MICA activates NK cells and co-stimulates T cells by interaction with its immunoreceptor NKG2D. In contrast, soluble MICA (sMICA) molecules impair the functions of NKG2D(+) T and NK cells, which may facilitate tumor cell escape from immunosurveillance. Here, we analyzed the clinical relevance of sMICA in 97 MM patients. sMICA (mean +/- SEM pg/ml) was significantly increased (p < 0.0001) in patients (429 +/- 20) compared to controls (230 20; N=43). Serial determination showed a strong correlation between increments of sMICA and paraprotein levels (r=0.543, p < 0.0001, N=49). sMICA levels > 305 pg/ml are associated with a poor overall (p=0.004) and progression-free survival (p=0.002). Multivariate analysis revealed sMICA as an independent predictive factor for overall (p=0.007) and progression-free survival (p=0.002). Thus, our results suggest sMICA as a potent prognostic marker in MM, which may be useful to identify risk patients. (c) 2006 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available